Congenital adrenal hyperplasia: Difference between revisions
Line 36: | Line 36: | ||
[[image:Adrenal Steroids.png|thumb|600px|center|frame|Adrenal steroid synthesis pathways in adrenal cortex and related enzymes <ref name="urlFile:Adrenal Steroids Pathways.svg - Wikimedia Commons">{{cite web |url=https://commons.wikimedia.org/wiki/File:Adrenal_Steroids_Pathways.svg|title=File:Adrenal Steroids Pathways.svg - Wikimedia Commons |format= |work= |accessdate=}}</ref>]] | [[image:Adrenal Steroids.png|thumb|600px|center|frame|Adrenal steroid synthesis pathways in adrenal cortex and related enzymes <ref name="urlFile:Adrenal Steroids Pathways.svg - Wikimedia Commons">{{cite web |url=https://commons.wikimedia.org/wiki/File:Adrenal_Steroids_Pathways.svg|title=File:Adrenal Steroids Pathways.svg - Wikimedia Commons |format= |work= |accessdate=}}</ref>]] | ||
==== Summary and Important Characteristics of the Different Congenital Adrenal Hyperplasia Subtypes: ==== | |||
<div style="-webkit-user-select: none;"> | |||
{| class="wikitable" align="center" style="border: 0px; font-size: 90%; margin: 3px;" | {| class="wikitable" align="center" style="border: 0px; font-size: 90%; margin: 3px;" | ||
! colspan="2" rowspan="2" align="center" style="background:#DCDCDC;" |Disease | ! colspan="2" rowspan="2" align="center" style="background:#DCDCDC;" |Disease | ||
Line 189: | Line 191: | ||
!Decreased | !Decreased | ||
|- | |- | ||
![[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]] | |||
| | | | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
Line 205: | Line 207: | ||
* [[Hypotension]] and [[hyperkalemia]] | * [[Hypotension]] and [[hyperkalemia]] | ||
|- | |- | ||
![[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |||
| | | | ||
* [[Deoxycorticosterone]] | * [[Deoxycorticosterone]] | ||
Line 219: | Line 221: | ||
* [[Virilization]] | * [[Virilization]] | ||
|- | |- | ||
![[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]] | |||
| | | | ||
* [[Deoxycorticosterone]] | * [[Deoxycorticosterone]] | ||
Line 237: | Line 239: | ||
* Minimal [[body hair]] | * Minimal [[body hair]] | ||
|- | |- | ||
![[3 beta-hydroxysteroid dehydrogenase deficiency]] | |||
| | | | ||
* [[Dehydroepiandrosterone]] | * [[Dehydroepiandrosterone]] | ||
Line 249: | Line 251: | ||
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis | * 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis | ||
|- | |- | ||
! Gestational [[hyperandrogenism]] | |||
| colspan="2" | | | colspan="2" | | ||
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | * Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | ||
Line 268: | Line 270: | ||
!Important clinical findings | !Important clinical findings | ||
|- | |- | ||
!Non-classic type of [[21-hydroxylase deficiency]] | |||
|Increased: | |Increased: | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
Line 279: | Line 281: | ||
* [[Virilization]] in females | * [[Virilization]] in females | ||
|- | |- | ||
![[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |||
|Increased: | |Increased: | ||
* DOC | * DOC | ||
Line 293: | Line 295: | ||
* [[Virilization]] | * [[Virilization]] | ||
|- | |- | ||
![[3 beta-hydroxysteroid dehydrogenase deficiency]] | |||
|Increased: | |Increased: | ||
* [[DHEA]] | * [[DHEA]] | ||
Line 309: | Line 311: | ||
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes. | * [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes. | ||
|- | |- | ||
![[Polycystic ovary syndrome ]] | |||
| | | | ||
* High [[DHEAS]] and [[androstenedione]] levels | * High [[DHEAS]] and [[androstenedione]] levels | ||
Line 320: | Line 322: | ||
* No evidence another diagnosis | * No evidence another diagnosis | ||
|- | |- | ||
![[Adrenal tumors]] | |||
| | | | ||
* Variable levels depends on [[tumor]] type | * Variable levels depends on [[tumor]] type | ||
Line 329: | Line 331: | ||
* Rapidly progressive symptoms | * Rapidly progressive symptoms | ||
|- | |- | ||
!Ovarian [[virilizing]] tumor | |||
| | | | ||
* Variable levels depends on [[tumor]] type | * Variable levels depends on [[tumor]] type | ||
Line 338: | Line 340: | ||
* Rapidly progressive symptoms | * Rapidly progressive symptoms | ||
|- | |- | ||
![[Cushing's syndrome]] | |||
| | | | ||
* Increase [[cortisol]] & metabolites | * Increase [[cortisol]] & metabolites | ||
Line 347: | Line 349: | ||
* [[Cushingoid appearance]] | * [[Cushingoid appearance]] | ||
|- | |- | ||
![[Hyperprolactinemia]] | |||
| | | | ||
* Normal levels of most of [[steroids]] | * Normal levels of most of [[steroids]] | ||
Line 356: | Line 358: | ||
|} | |} | ||
===Some types of congenital adrenal hyperplasia must be differentiated from diseases with [[primary amenorrhea]] and female [[external genitalia]] | ===Some types of congenital adrenal hyperplasia must be differentiated from diseases with [[primary amenorrhea]] and female [[external genitalia]]:<ref name="pmid21147889">{{cite journal |vauthors=Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C |title=Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients |journal=J. Clin. Endocrinol. Metab. |volume=96 |issue=2 |pages=296–307 |year=2011 |pmid=21147889 |doi=10.1210/jc.2010-1024 |url=}}</ref><ref name="pmid2164530">{{cite journal |vauthors=Moreira AC, Leal AM, Castro M |title=Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=71 |issue=1 |pages=86–91 |year=1990 |pmid=2164530 |doi=10.1210/jcem-71-1-86 |url=}}</ref><ref name="pmid999330">{{cite journal |vauthors=Heremans GF, Moolenaar AJ, van Gelderen HH |title=Female phenotype in a male child due to 17-alpha-hydroxylase deficiency |journal=Arch. Dis. Child. |volume=51 |issue=9 |pages=721–3 |year=1976 |pmid=999330 |pmc=1546244 |doi= |url=}}</ref><ref name="pmid226795">{{cite journal |vauthors=Biglieri EG |title=Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome |journal=J. Steroid Biochem. |volume=11 |issue=1B |pages=653–7 |year=1979 |pmid=226795 |doi= |url=}}</ref><ref name="pmid8929268">{{cite journal |vauthors=Saenger P |title=Turner's syndrome |journal=N. Engl. J. Med. |volume=335 |issue=23 |pages=1749–54 |year=1996 |pmid=8929268 |doi=10.1056/NEJM199612053352307 |url=}}</ref><ref name="pmid25813279">{{cite journal |vauthors=Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R |title=Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis |journal=Fertil. Steril. |volume=103 |issue=5 |pages=1297–304 |year=2015 |pmid=25813279 |doi=10.1016/j.fertnstert.2015.01.043 |url=}}</ref><ref name="pmid4432067">{{cite journal |vauthors=Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE |title=Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism |journal=Science |volume=186 |issue=4170 |pages=1213–5 |year=1974 |pmid=4432067 |doi= |url=}}</ref><ref name="pmid11344932">{{cite journal |vauthors=Schnitzer JJ, Donahoe PK |title=Surgical treatment of congenital adrenal hyperplasia |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=1 |pages=137–54 |year=2001 |pmid=11344932 |doi= |url=}}</ref>=== | ||
{| class="wikitable" | {| class="wikitable" | ||
Line 372: | Line 374: | ||
![[Karyotyping]] | ![[Karyotyping]] | ||
|- | |- | ||
!3-beta-hydroxysteroid dehydrogenase type 2 deficiency | |||
| | | | ||
* HSD3B2 [[gene]] [[mutation]] | * HSD3B2 [[gene]] [[mutation]] | ||
Line 391: | Line 393: | ||
[[XY]] and [[XX]] | [[XY]] and [[XX]] | ||
|- | |- | ||
![[17-alpha-hydroxylase deficiency]] | |||
| | | | ||
* [[CYP17A1|CYP17A1 gene mutation]] | * [[CYP17A1|CYP17A1 gene mutation]] | ||
Line 414: | Line 416: | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[Gonadal dysgenesis]] | |||
| | | | ||
* Mutations in [[SRY]], FOG2/ZFPM2, and WNT1 | * Mutations in [[SRY]], FOG2/ZFPM2, and WNT1 | ||
Line 435: | Line 437: | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[Testicular regression syndrome]] | |||
| | | | ||
* Loss of [[testicular]] function and tissue early in development | * Loss of [[testicular]] function and tissue early in development | ||
Line 453: | Line 455: | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[LH receptor|LH receptor defects]] | |||
| | | | ||
* [[LH receptor]] [[gene]] [[mutation]] on [[chromosome 2]] | * [[LH receptor]] [[gene]] [[mutation]] on [[chromosome 2]] | ||
Line 476: | Line 478: | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]] | |||
| | | | ||
* [[Autosomal recessive]] | * [[Autosomal recessive]] | ||
Line 499: | Line 501: | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[Androgen insensitivity syndrome]] | |||
| | | | ||
* [[Androgen receptor]] defect | * [[Androgen receptor]] defect | ||
Line 518: | Line 520: | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[Mullerian agenesis]] | |||
| | | | ||
* Mutations in ''[[WNT4]]'' | * Mutations in ''[[WNT4]]'' | ||
Line 537: | Line 539: | ||
[[XX]] | [[XX]] | ||
|- | |- | ||
![[Ovarian insufficiency|Primary ovarian insufficiency]] | |||
| | | | ||
* [[Genetic defects]] such as [[turner syndrome]], [[fragile X syndrome]], some other chromosomal defects | * [[Genetic defects]] such as [[turner syndrome]], [[fragile X syndrome]], some other chromosomal defects | ||
Line 555: | Line 557: | ||
[[XX]] | [[XX]] | ||
|- | |- | ||
![[Hypogonadotropic hypogonadism]] | |||
| | | | ||
* Functional, sellar masses | * Functional, sellar masses | ||
Line 575: | Line 577: | ||
[[XX]] | [[XX]] | ||
|- | |- | ||
! align="center" style="padding: 5px 5px; background: " | | |||
[[Turner syndrome]] | [[Turner syndrome]] | ||
| | | |
Revision as of 22:27, 13 September 2017
This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia.
Adrenal insufficiency | |
Adrenal gland |
Congenital adrenal hyperplasia main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Synonyms and keywords: Congenital adrenal hyperplasia; CAH; cah; Adrenal hyperplasia.
Overview
Congenital adrenal hyperplasia consists of several disorders result from defective enzymes and proteins involving in steroid and cortisol biosynthesis. Defects in steroid biosynthesis is caused by several genetic mutations and may lead to delayed, precocious puberty or ambiguous genitalia in each specific disorder. Decreasing cortisol level leads to releasing the inhibitory feedback on corticotropin (ACTH) production and high ACTH level causes cortisol precursor accumulation and overproduction of other hormones. The most common cause of congenital adrenal hyperplasia is 21-hydroxylase deficiency, which accounts for more than 95% of cases. Other causes include 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), and congenital lipoid adrenal hyperplasia.
Classification
Congenital adrenal hyperplasia is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance. Adrenal cortex can be devided to 3 different zones based on the hormonal synthesis ability and location:
- Zona glumerulosa is the outer layer of adrenal cortex, laying directly under the adrenal capsule
- Secretion: Aldosterone synthesis
- Zona fasciculate is the middle part of adrenal cortex, laying under zona glumerulosa
- Secretion: Cortisol synthesis
- Zona reticularis is the inner part of adrenal cortex, laying between zona fasciculate and adrenal medulla
- Secretion: Androgen synthesis
Impairment of each pathway and enzyme may lead to a specific subtype of congenital adrenal hyperplasia include:
- 21-hydroxylase deficiency
- 17 alpha-hydroxylase deficiency
- 11β-hydroxylase deficiency
- 3 beta-hydroxysteroid dehydrogenase deficiency
- Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
- Congenital lipoid adrenal hyperplasia
Summary and Important Characteristics of the Different Congenital Adrenal Hyperplasia Subtypes:
Disease | History and symptoms | Laboratory findings | Defective gene | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Blood pressure | Genitalia | Cortisol | Aldosterone | Androgens | Estrogens | Increased hormone precursors | Potassium levels | |||
21-hydroxylase deficiency | Classic type, salt-wasting | ↓ |
|
↓ | ↓↓ | ↑ | Relatively low | ↑ | ||
Classic type, non-salt-wasting | Normal |
|
↓ | ↓ | ↑ | Relatively low | Normal | CYP21A1 and CYP21A2 gene | ||
Non-classic type | Normal |
|
Normal | Normal | ↑ | Relatively low |
|
Normal | ||
17-α hydroxylase deficiency | ↑ |
|
Normal corticosterone
Normal cortisol |
↑ | ↓ | ↓ | ↓ | CYP17A1 | ||
11-β hydroxylase deficiency | ↑ |
|
↓ | ↑ | ↑ | Relatively low |
|
↓ | CYP11B1 | |
3 beta-hydroxysteroid dehydrogenase deficiency | ↓ |
|
↓ | ↓ | Male:↓
Female:↑ |
↓ | ↑ | HSD3B2 | ||
Cytochrome P450-oxidoreductase (POR) deficiency (ORD) | Normal |
|
↓ | Normal | ↓ | ↓ | Normal | Mutations in the flavoprotein co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase). | ||
Congenital lipoid adrenal hyperplasia | ↓ |
|
↓ | ↓ | ↓ | ↓ | None of precursors increased | ↓ | Gene mutations on chromosome 8, codes for a protein called steroid acute regulatory protein (StAR) |
Differential Diagnosis
Congenital adrenal hyperplasia must be differentiated from diseases that cause ambiguous genitalia:[2][3]
Disease name | Steroid status | Important clinical findings | |
---|---|---|---|
Increased | Decreased | ||
Classic type of 21-hydroxylase deficiency |
|
| |
11-β hydroxylase deficiency |
|
| |
17-α hydroxylase deficiency |
| ||
3 beta-hydroxysteroid dehydrogenase deficiency |
| ||
Gestational hyperandrogenism |
|
|
Congenital adrenal hyperplasia must be differentiated from diseases that cause virilization and hirsutism in female:[4][3][5]
Disease name | Steroid status | Other laboratory | Important clinical findings |
---|---|---|---|
Non-classic type of 21-hydroxylase deficiency | Increased:
|
|
|
11-β hydroxylase deficiency | Increased:
Decreased: |
|
|
3 beta-hydroxysteroid dehydrogenase deficiency | Increased:
Decreased: |
|
|
Polycystic ovary syndrome |
|
|
|
Adrenal tumors |
|
|
|
Ovarian virilizing tumor |
|
|
|
Cushing's syndrome |
|
||
Hyperprolactinemia |
|
|
Some types of congenital adrenal hyperplasia must be differentiated from diseases with primary amenorrhea and female external genitalia:[6][7][8][9][10][11][12][13]
Disease name | Cause | Differentiating | ||||||
---|---|---|---|---|---|---|---|---|
Findings | Uterus | Breast development | Testosterone | LH | FSH | Karyotyping | ||
3-beta-hydroxysteroid dehydrogenase type 2 deficiency |
|
Yes in female |
Yes in female |
Low |
Normal |
Normal |
||
17-alpha-hydroxylase deficiency |
|
No |
No |
Low |
Normal |
Normal |
||
Gonadal dysgenesis |
|
|
Yes |
Yes |
Low |
High |
High |
|
Testicular regression syndrome |
|
|
No |
No |
Low |
High |
High |
|
LH receptor defects |
|
No |
No |
Low |
High |
High |
||
5-alpha-reductase type 2 deficiency |
|
No |
No |
Normal male range |
High to normal |
High to normal |
||
Androgen insensitivity syndrome |
|
|
No |
Yes |
Normal male range |
Normal |
Normal |
|
Mullerian agenesis |
|
No |
Yes |
Normal female range |
Normal |
Normal |
||
Primary ovarian insufficiency |
|
|
Yes |
Yes |
Normal female range |
High |
High |
|
Hypogonadotropic hypogonadism |
|
|
Yes |
No |
Normal female range |
Low |
Normal |
|
|
|
Yes |
Yes |
Normal female range |
High |
High |
References
- ↑ "File:Adrenal Steroids Pathways.svg - Wikimedia Commons".
- ↑ Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
- ↑ 3.0 3.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
- ↑ Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
- ↑ Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=
- ↑ Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
- ↑ Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
- ↑ Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
- ↑ Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
- ↑ Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
- ↑ Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
- ↑ Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
- ↑ Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.